Drug Trial Radar · NCT01308567
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,168
Actual
Start
May 5, 2011
Primary completion
Sep 2015
Study completion May 2018
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: * To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m\^2 (Arm A) or 20 mg/m\^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic castration resistant prostate cancer (mCRPC) and not previously treated with chemotherapy. Secondary Objectives: * To evaluate safety in the 3 treatment arms. * To compare efficacy of cabazitaxel at 20 mg/m\^2 and 25 mg/m\^2 to docetaxel for: * Progression Free Survival (PFS) (RECIST 1.1) * Tumor progression free survival (RECIST 1.1) * Tumor response in participants with measurable disease (RECIST 1.1), * PSA response * PSA-Progression free survival (PSA-PFS). * Pain response in participants with stable pain at baseline * Pain progression free survival * Time to occurrence of any skeletal related events (SRE) * To compare Health-Related Quality of Life (HRQL). * To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.
Conditions
- Prostate Cancer
Interventions
Cabazitaxel (XRP6258)Drug
Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Docetaxel (XRP6976)Drug
Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
PrednisoneDrug
Pharmaceutical form: Tablet; Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )
Locations
167 sites in 25 countries. Site status is shown where the registry gives one.
Investigational Site Number 840004
Muscle Shoals, Alabama
Investigational Site Number 840009
Anaheim, California
Investigational Site Number 840014
Bakersfield, California
Investigational Site Number 840030
Sacramento, California
Investigational Site Number 840003
San Bernardino, California
Investigational Site Number 840012
San Francisco, California
Investigational Site Number 840019
Denver, Colorado
Investigational Site Number 840013
Boca Raton, Florida
Investigational Site Number 840035
Jacksonville, Florida
Investigational Site Number 840001
Port Saint Lucie, Florida
Investigational Site Number 840015
Decatur, Illinois
Investigational Site Number 840018
Wichita, Kansas
Investigational Site Number 840010
Paducah, Kentucky
Investigational Site Number 840008
New Orleans, Louisiana
Investigational Site Number 840006
Rockville, Maryland
Investigational Site Number 840238
Boston, Massachusetts
Investigational Site Number 840138
Boston, Massachusetts
Investigational Site Number 840038
Brookline, Massachusetts
Investigational Site Number 840005
Detroit, Michigan
Investigational Site Number 840021
Saint Louis Park, Minnesota
Investigational Site Number 840016
Kansas City, Missouri
Investigational Site Number 840020
Lincoln, Nebraska
Investigational Site Number 840017
East Orange, New Jersey
Investigational Site Number 840033
Albuquerque, New Mexico
Investigational Site Number 840036
Raleigh, North Carolina
Investigational Site Number 840011
Washington, North Carolina
Investigational Site Number 840026
Akron, Ohio
Investigational Site Number 840023
Cleveland, Ohio
Investigational Site Number 840032
Dunmore, Pennsylvania
Investigational Site Number 840007
Pawtucket, Rhode Island
Investigational Site Number 840037
Myrtle Beach, South Carolina
Investigational Site Number 840028
Chattanooga, Tennessee
Investigational Site Number 036016
Bankstown, Australia
Investigational Site Number 036008
Camperdown, Australia
Investigational Site Number 036015
Coffs Harbour, Australia
Investigational Site Number 036001
Concord, Australia
Investigational Site Number 036017
Fitzroy, Australia
Investigational Site Number 036003
Herston, Australia
Investigational Site Number 036010
Hornsby, Australia
Investigational Site Number 036012
Kurralta Park, Australia
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.